All patients
age >= 55 yr age >= 60 yr age >= 65 yr autoimmune disease corticosteroids: no corticosteroids: yes critical disease invasive ventilation no oxygen needed non invasive oxygen omicron variant BA.1 (B.1.1.529) severe disease solid organ transplant recipients subjects at risk
anti-inflammatoty and immuno-therapy in COVID-19 prophylaxis (excluding children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias Emergency room visit or hospitalizationdetailed results Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 0.12 [0.01; 2.35]
0.12 [0.01 ; 2.35 ] Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 1 0% 1,505 NA not evaluable deathsdetailed results BLAZE-2 US (Cohen), 2021 0.83 [0.25; 2.73]
Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 1.00 [0.14; 7.08]
0.87 [0.31 ; 2.41 ] BLAZE-2 US (Cohen), 2021, Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 2 0% 3,583 moderate not evaluable hospitalizationdetailed results PROVENT, 2022 0.04 [0.00; 0.63]
0.04 [0.00 ; 0.63 ] PROVENT, 2022 1 0% 4,685 NA not evaluable symptomatic Covid-19detailed results Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 0.17 [0.09; 0.33]
PROVENT, 2022 0.23 [0.10; 0.54]
0.19 [0.12 ; 0.33 ] Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021, PROVENT, 2022 2 0% 6,577 moderate not evaluable infection (PCR positive symptomatic or not)detailed results BLAZE-2 US (Cohen), 2021 0.43 [0.28; 0.67]
0.43 [0.28 ; 0.67 ] BLAZE-2 US (Cohen), 2021 1 0% 961 NA not evaluable severe COVID-19 occurrencedetailed results PROVENT, 2022 0.25 [0.01; 7.50]
0.25 [0.01 ; 7.50 ] PROVENT, 2022 1 0% 5,172 NA not evaluable serious adverse eventsdetailed results Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 2.97 [1.75; 5.03]
2.97 [1.75 ; 5.03 ] Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 1 0% 2,617 NA not evaluable adverse eventsdetailed results BLAZE-2 US (Cohen), 2021 2.02 [1.54; 2.64]
Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 0.62 [0.52; 0.74]
1.11 [0.35 ; 3.53 ] BLAZE-2 US (Cohen), 2021, Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 2 98% 3,792 moderate not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-23 10:35 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 89
- treatments: 546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525
- roots T: 290
